FDA Peptide Reclassification 2026: What Researchers Want Are Peptides coming off of the FDA Category 2 list? A legal breakdown. US FDA to convene expert panel to review wider access to some peptides Reuters PEPTIDES: THE 2026 FDA CRACKDOWN CONTROVERSYWhy this is MASSIVE SEO RIGHT NOW BPC 157 banned Everybody thinks research peptides are cheap until they actually do the math. A legal clinic prescription with doctor oversight, pharmacy regulation, and real monitoring might cost around $400 month for NAD+. Meanwhile, some HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled